Sonova Holding AG stock (CH0012549785): guidance cut and CEO change shake hearing-care specialist

Sonova Holding AG has lowered its sales outlook for the 2024/25 financial year and announced a CEO transition, while the stock reacted with noticeable volatility on the SIX Swiss Exchange. What this means for the Swiss hearing-care leader and US-focused investors.

Sonova Holding AG stock has come back into focus after the Swiss hearing-care specialist lowered its sales growth outlook for the 2024/25 financial year and outlined a leadership transition at the top of the group, developments that triggered a volatile share price reaction on the SIX Swiss Exchange according to company disclosures and exchange data as of May 2025, reported by Sonova investor information as of 05/2025 and complemented by market coverage from Reuters markets overview as of 05/2025.

As of: 28.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sonova
• Sector/industry: Hearing-care medical technology
• Headquarters/country: Stäfa, Switzerland
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Hearing instruments, cochlear implants, audiological services
• Home exchange/listing venue: SIX Swiss Exchange (ticker: SOON)
• Trading currency: Swiss franc (CHF)

Sonova Holding AG: core business model

Sonova Holding AG is a global provider of hearing-care solutions centered on the development, manufacturing and distribution of medical devices and services for people with hearing loss, including behind-the-ear and in-the-ear hearing instruments, cochlear implant systems and a network of audiological care clinics, according to the company’s corporate profile in its 2023/24 annual report published in May 2024, as summarized by Sonova investor information as of 05/2024.

The group operates under several specialist brands, such as Phonak and Unitron for hearing instruments as well as Advanced Bionics for cochlear implants, covering a wide range of price points and technological features to address diverse patient needs across age groups and income levels, based on product overviews in company materials reported by Sonova product information as of 2024.

Beyond devices, Sonova runs a vertically integrated business model that includes wholesale distribution to independent audiologists and retail operations through its own clinic chains, creating recurring revenue streams from fitting, maintenance and follow-up care services that complement one-off device sales, according to the group structure outlined in the 2023/24 annual report summarized by Sonova annual reporting as of 05/2024.

This combination of hardware, software, accessories and clinical services positions Sonova as a full-service provider in the hearing-care value chain, an approach that management has repeatedly described as central to its strategy of capturing lifetime value per patient and differentiating from pure-play device manufacturers, as highlighted in investor presentations cited by Sonova investor presentations as of 2024.

Main revenue and product drivers for Sonova Holding AG

According to Sonova’s 2023/24 annual report, hearing instruments represented the largest contribution to group sales in that financial year, followed by audiological services and cochlear implants, with management highlighting strong demand for premium and rechargeable devices as a key driver of growth, as outlined by Sonova annual report 2023/24 as of 05/2024.

The company has invested heavily in connectivity features, such as Bluetooth integration with smartphones and televisions, as well as in artificial intelligence–assisted sound processing, which are designed to improve speech understanding in noisy environments and to appeal to tech-savvy users, according to product descriptions and R&D commentary in Sonova materials summarized by Sonova innovation overview as of 2024.

In cochlear implants, Sonova focuses on implantable hearing systems for patients with severe to profound hearing loss, combining surgical implants with external sound processors, with the division benefiting from demographic trends and broader awareness of implant solutions as described in segment reporting in the 2023/24 annual report reported by Sonova annual reporting as of 05/2024.

The company also generates recurring revenue from batteries, chargers, wireless accessories and software updates, which can support margins and smooth revenue over time, particularly in mature markets such as North America and Western Europe where the installed base of devices is large, according to management commentary in capital markets material summarized by Sonova investor presentations as of 2024.

Why Sonova Holding AG matters for US investors

For US-focused investors, Sonova offers exposure to the global hearing-care market through a Swiss-listed stock with significant revenue generated in North America, where the group serves patients through wholesale partners and its own clinic network, according to regional breakdowns in the 2023/24 annual report summarized by Sonova annual report 2023/24 as of 05/2024.

The company competes in segments that overlap with US-listed peers in medical technology and hearing-care, making it relevant for investors comparing international medtech valuations and growth profiles across regions, a perspective frequently referenced in sector analyses for the hearing-care industry such as those cited by Reuters Sonova coverage as of 2025.

Because Sonova is listed on the SIX Swiss Exchange and reports in Swiss francs, US investors following the stock via international brokerage platforms need to consider both company fundamentals and currency movements when assessing the development of the share price in US dollar terms, as highlighted in general guidance on international investing from major broker research cited by SEC investor education as of 2024.

Conclusion

Sonova Holding AG remains one of the leading global players in hearing-care technology, combining devices and services across hearing instruments and cochlear implants, while recent guidance adjustments and leadership changes have renewed attention on execution and margin resilience against a backdrop of demographic tailwinds and competitive pressure, according to company communications and market commentary such as Sonova investor information as of 05/2025 and Ad-hoc-news.de as of 2025.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.